Larimar Therapeutics reported several updates on their FA program, nomlabofusp, in their second quarter 2024 operating and financial results press release today, August 7, 2024.
- Planning initiation of pharmacokinetic (PK) run-in study in adolescents and children with FA to begin by year-end 2024
- Planning initiation of global confirmatory study by mid-2025 with potential sites in the U.S., Europe, U.K., Canada, and Australia
- Joined TRACK-FA Neuroimaging Consortium as an industry partner.